Inclusion Criteria:  Confirmed diagnosis of Crohn's Disease (CD) for at least 3 months prior to Baseline of the Induction Period. Crohn's Disease Activity Index (CDAI) score 220 to 450 at Baseline of the Induction Period. Endoscopic evidence of mucosal inflammation as documented by an Simple Endoscopic Score for Crohn's Disease (SES-CD) of >= 6 for ileocolonic or colonic disease or SES-CD of >= 4 for isolated ileal disease as scored by a central reader. All eligible scores must exclude the presence of narrowing component. Demonstrated intolerance or inadequate response to one or more of the following biologic agents: infliximab, adalimumab, certolizumab pegol, vedolizumab, natalizumab, or ustekinumab.  Exclusion Criteria:  - Participants with prior intolerance to adalimumab.